ReadCoor has received a multi-year grant from the Bill & Melinda Gates Foundation for its proprietary spatial sequencing technology to probe into causes of childhood mortality.

The company will use this grant to develop technology using its FISSEQ platform to detect pathogens directly from their transcriptomes and genomes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FISSEQ is a fluorescent in-situ sequencing platform developed for highly multiplexed analysis of RNA, DNA and other molecular features without removing cells from their tissue.

The platform has demonstrated its utility in infectious diseases, as well as other applications such as brain mapping, gene therapy, immuno-therapy, oncology, neurodegenerative diseases, regenerative medicine and others.

ReadCoor co-founder and CEO Shawn Marcell said: “It is a great privilege to partner with the Bill & Melinda Gates Foundation in this important effort to reduce childhood mortality in developing countries.

See Also:

“We are committed to applying the FISSEQ platform for the benefit of humankind and we applaud the Gates Foundation for its vision and willingness to support innovative approaches to age-old problems.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The foundation will fund up to $2.5m over the next two years to support the development of FISSEQ-based diagnostics and analytical tools."

The foundation will fund up to $2.5m over the next two years to support the development of FISSEQ-based diagnostics and analytical tools to analyse pathogens responsible for early childhood ailments.

FISSEQ’s in-situ sequencing of tissue enables it to identify each pathogen’s unique genetic sequence and location in the tissue which is correlated with mortality marker, such as inflammation.

The epidemiological approach is to pave the way to adopt disease surveillance efforts and prepare to combat outbreaks.